SARS-CoV-2 Vaccines
Contents
SARS-CoV-2
Introduction
SARS-CoV-2 Vaccines
Introduction
Creative Biolabs’
Services
SARS-CoV-2
Vaccine Pipeline
Human cell
Body
ACE2 Receptor
In Vitro
Spike Protein M Protein
friends 下载
RNA
Coronavirus
gathering
Viral RNA translated
into proteins
Virus enters the body
1.Vesicle
Virus enters a cell
2.Virus fus with vesicle and
its RNA is relead
3.Virus asmbly
4.Virus relea
5.The virus us its surface spike protein to lock onto ACE2 receptors on the surface of human cells. Once inside, the cells
translate the virus’s RNA to produce more virus.
Coronavirus Infection
doppelgangerSARS-CoV-2 Introduction
- Virus Infection
grapeVirus ingested by antigen-prenting cell
(APC)
T-helper Cell
B Cell
Cytotoxic T cell
Anti-coronavirus Antibody
Long-lived memory B and T cells that recognize the virus can protect the body for months or years, providing immunity.
Destroy
infected cells
Viral Peptide
Specialized antigen-prenting cells
engulf the virus and display portions of it to activate T-helper cells.
Immune respon
T-helper cells enable other immune
sick是什么意思
respons: B cells make antibodies that can block the virus from infecting cells, as well as mark the virus for destruction. Cytotoxic T cells identify and destroy virus-infected cells.
SARS-CoV-2 Introduction - Immune Respon
Memory Cells
MHC Ⅱ
R&D CLINICAL
LOGISTICS
SARS-CoV-2 Vaccines Introduction
- Vaccine Development
Platform choice
< proper Spike trimer formation, folding and glycan structure (Protein), generation of neutralizing Abs, excellent我等你英文
love of irixpression (DNA, RNA), Efficient cell transduction (Viral vector), etc .
Neutralizing Abs, robust and appropriate T-cell activation and cytokines, SARS-Cov-2 viral killing in challenge studies, protection from COVID symptoms.
PhaⅠ
Ø
Safety强调句型
Idea vaccine ØBillions of dos ØElicits effective，long-lasting immunity
Manufacturing capabilities
Side-effects
ØReaction site/systemic Aes ØADE, ADCC, CDC, VAERD
中译西Lack of efficacy
ØMinimal/no protection
Design 1-5 target
Prep small batches
In vitro testing
Targeting lection
Target validation
ØSARS-CoV-2 infection assays Vero cells Ø
Positive T-cell respon
Preclinical testing in vitro in cell culture and in vivo in animals
Pha Ⅱ
ØSafety Ø
Efficacy
Pha Ⅲ
asterixØEfficacy ØProtection COVID-19
Scale up
Worldwide distribution Storage
Supply chain
